Conflicts of interest Authors declare no conflict of interest.
Mesenchymal stromal cells for tissue-engineered tissue and organ replacements
Version of Record online: 16 JAN 2012
© 2012 The Authors Transplant International © 2012 European Society for Organ Transplantation
Volume 25, Issue 4, pages 369–382, April 2012
How to Cite
Baiguera, S., Jungebluth, P., Mazzanti, B. and Macchiarini, P. (2012), Mesenchymal stromal cells for tissue-engineered tissue and organ replacements. Transplant International, 25: 369–382. doi: 10.1111/j.1432-2277.2011.01426.x
- Issue online: 14 MAR 2012
- Version of Record online: 16 JAN 2012
- Received: 9 June 2011 Revision requested: 9 July 2011 Accepted: 15 December 2011
- mesenchymal stromal cells;
- tissue engineering
Mesenchymal stromal cells (MSCs), a rare heterogeneous subset of pluripotent stromal cells that can be easily isolated from different adult tissues, in vitro expanded and differentiated into multiple lineages, are immune privileged and, more important, display immunomodulatory capacities. Because of this, they are the preferred cell source in tissue-engineered replacements, not only in autogeneic conditions, where they do not evoke any immune response, but especially in the setting of allogeneic organ and tissue replacements. However, more preclinical and clinical studies are requested to completely understand MSC’s immune biology and possible clinical applications. We herein review the immunogenicity and immunomodulatory properties of MSCs, their possible mechanisms and potential clinical use for tissue-engineered organ and tissue replacement.